title: Effect of phosphatidylinositol-3 kinase inhibition on ovotoxicity caused by 4-vinylcyclohexene diepoxide and 7, 12-dimethylbenz[a]anthracene in neonatal rat ovaries.
abstract: 4-vinylcyclohexene diepoxide (VCD) is an ovotoxicant that specifically destroys primordial and small primary follicles in the ovaries of mice and rats. In contrast, 7,12-dimethylbenz[a]anthracene (DMBA) is ovotoxic to all ovarian follicle classes. This study investigated phosphatidylinositol-3 kinase signaling involvement in VCD- and DMBA-induced ovotoxicity. Postnatal day (PND) 4 Fischer 344 (F344) rat whole ovaries were cultured for 2-12 days in vehicle control, VCD (30 microM), or DMBA (1 microM), +/-PI3 kinase inhibitor LY294002 (20 microM) or its inactive analog LY303511 (20 microM). Following culture, ovaries were histologically evaluated, and healthy follicles were classified and counted. PI3 kinase inhibition had no effect on primordial follicle number, but reduced (P<0.05) small primary and larger follicles beginning on day 4. VCD caused primordial and small primary follicle loss (P<0.05) beginning on day 6. With PI3 kinase inhibition, VCD did not affect primordial follicles (P>0.05) at any time, but did cause loss (P<0.05) of small primary follicles. DMBA exposure caused primordial and small primary follicle loss (P<0.05) on day 6. Further, DMBA-induced primordial and small primary follicle loss was greater with PI3 kinase inhibition (P<0.05) than with DMBA alone. These results support that (1) PI3 kinase mediates primordial to small primary follicle recruitment, (2) VCD, but not DMBA, enhances ovotoxicity by increasing primordial to small primary follicle recruitment, and (3) in addition to xenobiotic-induced ovotoxicity, VCD is also a useful model chemical with which to elucidate signaling mechanisms involved in primordial follicle recruitment.
authors.affiliation: Department of Physiology, University of Arizona, 1501 N. Campbell Ave., #4122, Tucson, AZ 85724-5051, USA.
authors.forename: Aileen F
authors.initials: AF
authors.lastname: Keating
authors.forename: Connie
authors.initials: C
authors.lastname: J Mark
authors.forename: Nivedita
authors.initials: N
authors.lastname: Sen
authors.forename: I Glenn
authors.initials: IG
authors.lastname: Sipes
authors.forename: Patricia B
authors.initials: PB
authors.lastname: Hoyer
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D000818:Animals; D000831:Animals, Newborn; D002867:Chromones / Q000494:pharmacology*; D053138:Cyclohexenes / Q000633:toxicity*; D005260:Female; D066298:In Vitro Techniques; D009025:Morpholines / Q000494:pharmacology*; D010049:Ovarian Diseases / Q000139:chemically induced / Q000473:pathology; D006080:Ovarian Follicle / Q000187:drug effects* / Q000473:pathology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D013997:Time Factors; D014753:Vinyl Compounds / Q000633:toxicity*
chemical_list: D002867:Chromones; D053138:Cyclohexenes; D009025:Morpholines; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010879:Piperazines; D014753:Vinyl Compounds; C093555:LY 303511; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D015127:9,10-Dimethyl-1,2-benzanthracene; C012606:4-vinyl-1-cyclohexene dioxide
references.citation: Dev Biol. 2005 May 15;281(2):160-70
references.pmid: 15893970
references.citation: Toxicol Appl Pharmacol. 1990 Sep 15;105(3):372-81
references.pmid: 2237912
references.citation: Development. 1990 Dec;110(4):1057-69
references.pmid: 1712701
references.citation: Dev Biol. 2006 Nov 1;299(1):1-11
references.pmid: 16970938
references.citation: Toxicol Appl Pharmacol. 2002 Oct 15;184(2):107-15
references.pmid: 12408955
references.citation: Biol Reprod. 2001 Nov;65(5):1489-95
references.pmid: 11673266
references.citation: Science. 2008 Feb 1;319(5863):611-3
references.pmid: 18239123
references.citation: Toxicol Appl Pharmacol. 1996 Aug;139(2):394-401
references.pmid: 8806857
references.citation: Biol Reprod. 1991 Oct;45(4):547-52
references.pmid: 1721549
references.citation: Mol Endocrinol. 2007 Sep;21(9):2189-202
references.pmid: 17565040
references.citation: Dev Biol. 2008 Sep 1;321(1):197-204
references.pmid: 18601916
references.citation: J Biol Chem. 1994 Feb 18;269(7):5241-8
references.pmid: 8106507
references.citation: Nat Genet. 2001 Aug;28(4):355-60
references.pmid: 11455387
references.citation: Toxicol Appl Pharmacol. 1996 Aug;139(2):402-10
references.pmid: 8806858
references.citation: Biol Reprod. 2002 Sep;67(3):718-24
references.pmid: 12193377
references.citation: Biol Reprod. 2001 Jul;65(1):87-93
references.pmid: 11420227
references.citation: Toxicol Sci. 2007 Apr;96(2):327-34
references.pmid: 17204581
references.citation: Science. 2003 Jul 11;301(5630):215-8
references.pmid: 12855809
references.citation: Endocrinology. 1999 Sep;140(9):4262-71
references.pmid: 10465300
references.citation: Toxicol Appl Pharmacol. 2000 Sep 15;167(3):191-8
references.pmid: 10986010
references.citation: Reprod Toxicol. 1999 Jan-Feb;13(1):67-75
references.pmid: 10080302
references.citation: Int Rev Cytol. 1991;124:43-101
references.pmid: 2001918
references.citation: Reprod Toxicol. 1994 Nov-Dec;8(6):509-14
references.pmid: 7881202
references.citation: Biol Reprod. 2008 Aug;79(2):318-27
references.pmid: 18448842
references.citation: Toxicol Appl Pharmacol. 2009 Feb 1;234(3):361-9
references.pmid: 19027032
references.citation: EMBO J. 2000 Mar 15;19(6):1312-26
references.pmid: 10716931
references.citation: Development. 1990 Aug;109(4):911-23
references.pmid: 1699718
references.citation: Dev Biol. 1997 Apr 1;184(1):122-37
references.pmid: 9142989
references.citation: Mol Reprod Dev. 1996 Apr;43(4):458-69
references.pmid: 9052937